heart infarction ischemia-reperfusion injury
Conditions
Interventions
pretreatment with Persantin Retard, 2dd 200mg or placebo.
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: ·Patients accepted for elective single, native vessel (left anterior descending, right coronary artery or ramus circumflexus (LAD, RCA or RCX)) PCI in the RUNMC or RUNMC cardiology policlinic patients undergoing diagnostic coronary angiography. ·Troponin-I
Exclusion criteria
Exclusion criteria: · unstable angina · recent myocardial infarction (STEMI or non-STEMI), during two weeks prior to inclusion · 3-Vessel disease as seen on coronary angiogram · Stenotic laesion in mainstem as seen on coronary angiogram · CABG in medical history · asthma (recurrent episodes of dyspnea and wheezing, or usage of prescribed inhalation medication: i.e. corticosteroids or B2-agonists) · Diabetes Mellitus type I (insuline dependent) · Use of prescribtioned oral anticoagulants (coumarine derivates) · Use of oral corticosteroids · Use of sulfonylurea derivates (glibenclamide, tolbutamide, gliclazide, glimepiride) · Chronic use of Non Steroid Anti-Inflammatory Drugs (NSAID*s) · Administration of Repro® during PCI (complicated procedure)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Periprocedural troponin-I release measured 8 hours after PCI. | — |
Secondary
| Measure | Time frame |
|---|---|
| To study the effect of pretreatment with Persantin (retard, 2dd200mg) in patients undergoing PCI on biomarkers reflecting atherosclerotic activity (hs-CRP, PLA2 and PTX3) before and after pretreatment with Persantin and 8 hours after PCI. | — |
Countries
Netherlands
Outcome results
None listed